AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL)

ID Number 80-0066-00073

Principal Investigator(s)
Birte Wistinghausen

Department(s) or Division(s)


The purpose of this study is:

  • Compare the effects, good and/or bad, of a higher dose of oral methotrexate with the standard dose for the treatment of children with Average Risk B-precursor ALL. In this study, your child will get either the higher dose, or the standard dose of oral methotrexate. Your child will not get both.

Contact Information
Katrina Watson
(212) 241-6906

Recruiting Patients: Yes